Gołacki Jakub, Matyjaszek-Matuszek Beata
Chair and Department of Endocrinology, Diabetology and Metabolic Diseases, Medical University of Lublin, Lublin, Poland.
Chair and Department of Endocrinology, Diabetology and Metabolic Diseases, Medical University of Lublin, Lublin, Poland.
Adv Med Sci. 2024 Mar;69(1):208-215. doi: 10.1016/j.advms.2024.04.001. Epub 2024 Apr 9.
Obesity continues to be a significant global health concern, giving rise to various complications. This review article explores the current standards and emerging innovations in diagnosing and treating obesity, including recent disease name change, staging system or therapeutic goals. This narrative review has been based on recent scientific articles from PubMed database, limiting the scope of topics to current standards and upcoming developments and breakthroughs in the diagnosis and treatment of obesity. The educational and informative nature of the review has been maintained in order to make the information presented accessible to both researchers and clinical practitioners. The recognition of diverse obesity phenotypes has prompted a paradigm shift towards a complex and patient-centered approach to diagnosis and therapy. Pharmacotherapy for obesity is evolving rapidly, with ongoing research focusing on novel molecular targets and metabolic pathways. Promising developments include dual or triple incretin analogs, oral incretin drugs, neurotransmitter-based therapies, muscle mass-increasing treatments, and therapies targeting visceral adipose tissue browning. Despite current evidence-based international standards, the field of obesity diagnosis and treatment continues to expand, with new diagnostic tools and pharmacotherapies potentially replacing current practices. Therapeutic management should be tailored to individual patients, considering obesity phenotype, health status, lifestyle, and preferences. Looking ahead, the future holds promising opportunities for obesity management, but further research is required to assess the efficacy and safety of emerging therapies. A multifactorial and personalized approach will be pivotal in addressing the diverse challenges posed by obesity.
肥胖仍然是一个重大的全球健康问题,会引发各种并发症。这篇综述文章探讨了肥胖诊断和治疗的当前标准以及新出现的创新方法,包括最近的疾病名称变化、分期系统或治疗目标。这篇叙述性综述基于来自PubMed数据库的近期科学文章,将主题范围限制在肥胖诊断和治疗的当前标准以及即将出现的发展和突破方面。综述保持了教育性和信息性,以便使所呈现的信息对研究人员和临床医生都易于理解。对多种肥胖表型的认识促使人们向一种复杂且以患者为中心的诊断和治疗方法转变。肥胖的药物治疗正在迅速发展,正在进行的研究集中在新的分子靶点和代谢途径上。有前景的发展包括双重或三重肠促胰岛素类似物、口服肠促胰岛素药物、基于神经递质的疗法、增加肌肉量的治疗方法以及针对内脏脂肪组织褐变的疗法。尽管有当前基于证据的国际标准,但肥胖诊断和治疗领域仍在不断扩展,新的诊断工具和药物疗法可能会取代当前的做法。治疗管理应根据个体患者进行调整,考虑肥胖表型、健康状况、生活方式和偏好。展望未来,肥胖管理有充满希望的机会,但需要进一步研究来评估新出现疗法的疗效和安全性。一种多因素和个性化的方法对于应对肥胖带来的各种挑战至关重要。